Introduction Iatrogenic hyperprolactinaemia (IHPRL) has been more frequently related to
some antipsychotic drugs that provoke an intense blockade of dopamine D2 receptors …

Background Antipsychotic switching is routine in clinical practice, although it remains
unclear which is the preferable switching method: immediate discontinuation of the current …

Background Most women with psychotic disorders and bipolar disorders have children but
their pregnancies are at risk of adverse psychiatric and fetal outcome. The extent of …

Lumateperone, an antipsychotic that is US Food and Drug Administration-approved for the
treatment of schizophrenia, has a novel mechanism of action that may confer beneficial …

Background Lumateperone is a mechanistically novel agent FDA-approved for the treatment
of schizophrenia. Efficacy and favorable tolerability of lumateperone were demonstrated in 2 …

Pregnancy in women with severe mental illness is associated with adverse outcomes for
mother and infant. There are limited data on prevalence and predictors of relapse in …

Background Antipsychotics are used in Parkinson disease (PD) to treat psychosis, mood,
and behavioral disturbances. Commonly used antipsychotics differ substantially in their …

Background Healthcare decision makers require accurate long-term economic models to
evaluate the cost-effectiveness of new mental health interventions. Aims To assess the …

Background Differences in effectiveness and tolerability between different atypical
antipsychotics may affect schizophrenic patients' treatment adherence or prognosis …

Introducción La hiperprolactinemia iatrogénica (HPRLi) se ha descrito con más frecuencia
con algunos antipsicóticos, dependiendo de su capacidad de bloqueo de los receptores de …